1. Home
  2. LBPH vs COUR Comparison

LBPH vs COUR Comparison

Compare LBPH & COUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LBPH
  • COUR
  • Stock Information
  • Founded
  • LBPH 2020
  • COUR 2012
  • Country
  • LBPH United States
  • COUR United States
  • Employees
  • LBPH N/A
  • COUR N/A
  • Industry
  • LBPH Biotechnology: Pharmaceutical Preparations
  • COUR Computer Software: Prepackaged Software
  • Sector
  • LBPH Health Care
  • COUR Technology
  • Exchange
  • LBPH Nasdaq
  • COUR Nasdaq
  • Market Cap
  • LBPH 1.4B
  • COUR 1.2B
  • IPO Year
  • LBPH 2021
  • COUR 2021
  • Fundamental
  • Price
  • LBPH $59.81
  • COUR $7.06
  • Analyst Decision
  • LBPH Buy
  • COUR Buy
  • Analyst Count
  • LBPH 8
  • COUR 11
  • Target Price
  • LBPH $52.29
  • COUR $11.66
  • AVG Volume (30 Days)
  • LBPH 834.8K
  • COUR 2.6M
  • Earning Date
  • LBPH 11-07-2024
  • COUR 10-24-2024
  • Dividend Yield
  • LBPH N/A
  • COUR N/A
  • EPS Growth
  • LBPH N/A
  • COUR N/A
  • EPS
  • LBPH N/A
  • COUR N/A
  • Revenue
  • LBPH N/A
  • COUR $684,374,000.00
  • Revenue This Year
  • LBPH N/A
  • COUR $11.00
  • Revenue Next Year
  • LBPH N/A
  • COUR $6.69
  • P/E Ratio
  • LBPH N/A
  • COUR N/A
  • Revenue Growth
  • LBPH N/A
  • COUR 12.36
  • 52 Week Low
  • LBPH $3.60
  • COUR $6.29
  • 52 Week High
  • LBPH $59.95
  • COUR $21.26
  • Technical
  • Relative Strength Index (RSI)
  • LBPH 78.81
  • COUR 41.65
  • Support Level
  • LBPH $59.47
  • COUR $6.76
  • Resistance Level
  • LBPH $59.85
  • COUR $7.64
  • Average True Range (ATR)
  • LBPH 0.20
  • COUR 0.27
  • MACD
  • LBPH -0.84
  • COUR -0.02
  • Stochastic Oscillator
  • LBPH 86.36
  • COUR 25.84

About LBPH Longboard Pharmaceuticals Inc.

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

Share on Social Networks: